An API supplier should not advance merely because it offers an attractive price. Before GMP certificates, CEPs or Drug Master Files can be evaluated meaningfully, the buyer must know exactly who manufactures the API, what material is being offered and how it will reach the buyer.
The same manufacturer may operate several sites with different functions and different regulatory histories. Evidence for a warehouse, testing laboratory or finished-product operation cannot automatically support API synthesis at another location.
API supplier qualification—sometimes called API vendor qualification—is the documented, risk-based process of establishing that a defined API source can meet GMP, technical, regulatory and quality requirements in routine commercial supply.
These terms are frequently used throughout the pharmaceutical industry, yet they are sometimes misunderstood or used interchangeably. Although API manufacturers, CMOs, and CDMOs all contribute to bringing medicines to market, they serve different purposes and often become involved at different stages of a product’s lifecycle.
For decades, international pharmaceutical business development relied on a relatively predictable set of channels. Companies met at industry exhibitions, developed distributor networks, exchanged referrals through consultants, or built relationships slowly through years of regional market presence. That model is changing.
